Full Year 2024 Results Key Financial Results Net loss: US$59.6m (loss narrowed ...

BofA analyst Alec Stranahan lowered the firm’s price target on BioXcel Therapeutics (BTAI) to $1 from $4 and keeps an Underperform rating on ...

Reports Q4 revenue $366k, consensus $718.26k. “We believe that our SERENITY program presents an exciting opportunity to address a substantial ...

Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 ...

The Chattogram City Corporation (CCC) has begun an experimental deployment of Bacillus thuringiensis israelensis (BTI), a ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) was the target of a significant increase in short interest in the ...

Fintel reports that on March 19, 2025, Rodman & Renshaw initiated coverage of BioXcel Therapeutics (NasdaqCM:BTAI) with a Buy ...

Artificial Intelligence (AI) and Machine Learning (ML) play a pivotal role in precision oncology, analyzing vast datasets, ...

We recently published a list of 12 Incredibly Cheap Dividend Stocks to Buy Now. In this article, we are going to take a look ...

Another company involved in using AI to repurpose failed drugs – as well as drugs that have already been approved – is ...

He joins MindMed from BioXcel Therapeutics, where he served as CCO overseeing the launch of the company’s first acute treatment of agitation associated with schizophrenia and bipolar disorder. Prior ...